Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Gilead: Five-Year Hepsera Data Show Continued Efficacy In HBV

Nov. 16, 2005

By Jennifer Boggs

Gilead: Five-Year Hepsera Data Show Continued Efficacy In HBV

Nov. 16, 2005

By Jennifer Boggs

Speedel Presents Confirmatory Positive SPP301 Phase II Data

Nov. 15, 2005

By Jennifer Boggs

Speedel Presents Confirmatory Positive SPP301 Phase II Data

Nov. 15, 2005

By Jennifer Boggs

Aphton Ends Sanofi Deal, Seeks New Insegia Partner

Nov. 11, 2005

By Jennifer Boggs

PTC Raises $26M Privately; Lead Drug To Start Phase II

Nov. 11, 2005

By Jennifer Boggs

Aphton Ends Sanofi Deal, Seeks New Insegia Partner

Nov. 11, 2005

By Jennifer Boggs

PTC Raises $26M Privately; Lead Drug To Start Phase II

Nov. 11, 2005

By Jennifer Boggs

Versant Closes $400M Fund, Seeks Early Stage Companies

Nov. 10, 2005

By Jennifer Boggs

Versant Closes $400M Fund, Seeks Early Stage Companies

Nov. 10, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...